264 related articles for article (PubMed ID: 17088579)
1. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.
Desai J; Yassa L; Marqusee E; George S; Frates MC; Chen MH; Morgan JA; Dychter SS; Larsen PR; Demetri GD; Alexander EK
Ann Intern Med; 2006 Nov; 145(9):660-4. PubMed ID: 17088579
[TBL] [Abstract][Full Text] [Related]
2. Summaries for patients. Underactive thyroid function after treatment with sunitinib for gastrointestinal cancer.
Ann Intern Med; 2006 Nov; 145(9):I44. PubMed ID: 17088575
[No Abstract] [Full Text] [Related]
3. Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression.
Kappers MH; van Esch JH; Smedts FM; de Krijger RR; Eechoute K; Mathijssen RH; Sleijfer S; Leijten F; Danser AH; van den Meiracker AH; Visser TJ
J Clin Endocrinol Metab; 2011 Oct; 96(10):3087-94. PubMed ID: 21816788
[TBL] [Abstract][Full Text] [Related]
4. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake.
Mannavola D; Coco P; Vannucchi G; Bertuelli R; Carletto M; Casali PG; Beck-Peccoz P; Fugazzola L
J Clin Endocrinol Metab; 2007 Sep; 92(9):3531-4. PubMed ID: 17595247
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib-induced acute severe hypothyroidism in a case of metastatic gastrointestinal stromal tumor: A case report.
Manir KS; Banerjee D; Bhowmick R; Roy C
J Cancer Res Ther; 2018 Sep; 14(Supplement):S818-S819. PubMed ID: 30249914
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib-induced thyrotoxicosis followed by persistent hypothyroidism with shrinkage of thyroid volume.
Sakurai K; Fukazawa H; Arihara Z; Yoshida K
Tohoku J Exp Med; 2010 Sep; 222(1):39-44. PubMed ID: 20814176
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity.
Wong E; Rosen LS; Mulay M; Vanvugt A; Dinolfo M; Tomoda C; Sugawara M; Hershman JM
Thyroid; 2007 Apr; 17(4):351-5. PubMed ID: 17465866
[TBL] [Abstract][Full Text] [Related]
8. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation.
Wolter P; Stefan C; Decallonne B; Dumez H; Bex M; Carmeliet P; Schöffski P
Br J Cancer; 2008 Aug; 99(3):448-54. PubMed ID: 18665181
[TBL] [Abstract][Full Text] [Related]
9. [Thyroid dysfunction in patients with advanced renal cell carcinoma treated with sunitinib: a multifactorial issue].
Fuertes Zamorano N; De Miguel Novoa MP; Molino González A; Díaz Pérez JÁ; Rojas-Marcos PM; Montañez Zorrilla MC
Endocrinol Nutr; 2010 Dec; 57(10):486-91. PubMed ID: 20702151
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma.
Sato S; Muraishi K; Tani J; Sasaki Y; Tokubuchi I; Tajiri Y; Yamada K; Suekane S; Miyajima J; Matsuoka K; Hiromatsu Y
Endocr J; 2010; 57(10):873-80. PubMed ID: 20733268
[TBL] [Abstract][Full Text] [Related]
11. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Rini BI; Tamaskar I; Shaheen P; Salas R; Garcia J; Wood L; Reddy S; Dreicer R; Bukowski RM
J Natl Cancer Inst; 2007 Jan; 99(1):81-3. PubMed ID: 17202116
[TBL] [Abstract][Full Text] [Related]
12. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma.
Grossmann M; Premaratne E; Desai J; Davis ID
Clin Endocrinol (Oxf); 2008 Oct; 69(4):669-72. PubMed ID: 18394019
[TBL] [Abstract][Full Text] [Related]
13. Thyroid Dysfunction in Patients with Metastatic Carcinoma Treated with Sunitinib: Is Thyroid Autoimmunity Involved?
Pani F; Atzori F; Baghino G; Boi F; Tanca L; Ionta MT; Mariotti S
Thyroid; 2015 Nov; 25(11):1255-61. PubMed ID: 26414109
[TBL] [Abstract][Full Text] [Related]
14. Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate. Related or unrelated adverse events?
Tassi R; Baldazzi V; Lapini A; Carini M; Mazzanti R
Clin Genitourin Cancer; 2015 Apr; 13(2):e101-5. PubMed ID: 25450040
[TBL] [Abstract][Full Text] [Related]
15. Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction?
Rogiers A; Wolter P; Op de Beeck K; Thijs M; Decallonne B; Schöffski P
Thyroid; 2010 Mar; 20(3):317-22. PubMed ID: 20144039
[TBL] [Abstract][Full Text] [Related]
16. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.
Torino F; Corsello SM; Longo R; Barnabei A; Gasparini G
Nat Rev Clin Oncol; 2009 Apr; 6(4):219-28. PubMed ID: 19333228
[TBL] [Abstract][Full Text] [Related]
17. The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study.
Baldazzi V; Tassi R; Lapini A; Santomaggio C; Carini M; Mazzanti R
Urol Oncol; 2012 Sep; 30(5):704-10. PubMed ID: 20884255
[TBL] [Abstract][Full Text] [Related]
18. Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function.
Kitajima K; Takahashi S; Maeda T; Yoshikawa T; Ohno Y; Fujii M; Miyake H; Fujisawa M; Sugimura K
Eur J Radiol; 2012 Sep; 81(9):2060-5. PubMed ID: 21724350
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients.
Buda-Nowak A; Kucharz J; Dumnicka P; Kuzniewski M; Herman RM; Zygulska AL; Kusnierz-Cabala B
Med Oncol; 2017 Apr; 34(4):68. PubMed ID: 28343336
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib: new drug. For some gastrointestinal stromal tumours.
Prescrire Int; 2007 Aug; 16(90):138-41. PubMed ID: 17724833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
